Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 1929 • ACR Convergence 2025
Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still’s Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD)): Analysis of a US National Administrative Claims Database
Michael Marrone¹, Christopher McPherson² and Abiola Oladapo³, ¹Sobi Inc., Mt Pleasant, SC, ²Sobi, University City, MO, ³Sobi INC, Waltham, MA
Background/Purpose: Macrophage activation syndrome (MAS) is a severe, life-threatening complication of rheumatologic disease. MAS is a form of secondary hemophagocytic lymphohistiocytosis which occurs most frequently…
Abstract Number: 1274 • ACR Convergence 2025
Analysis of Vaccination Compliance In Patients With Juvenile Idiopathic Arthritis At The Rheumatology Transitional Consultation
Andres Perez Hurtado¹, Jose Ivorra Cortes², ELENA GRAU GARCIA³, Miguel Simeo Vinaixa⁴, Iago Alcantara Alvarez⁴, Belen Villanueva Manes⁵, Alba Maria Torrat Noves⁶, Daniel Ramos Castro⁷, Pablo Muñoz Martinez⁴, Laura mas sanchez⁸, Berta López Montesinos⁹, Lucía Lacruz Pérez¹⁰ and José Andrés Román Ivorra¹¹, ¹Hospital Universitario y Politècnico La Fe, València, Comunidad Valenciana, Spain, ²Hospital Universitario La Fe, Valencia, Comunidad Valenciana, Spain, ³HUP La Fe, Valencia, Comunidad Valenciana, Spain, ⁴Rheumatology Department. HUP La Fe, Valencia, Spain, ⁵Hospital La Fe, València, Spain, ⁶Hospital Universitari i Politècnic La Fe de Valencia, Valencia, Spain, ⁷Hospital Universitari i Politecnic La Fe, Valencia, Spain, ⁸Hospital Universitario y Politécnico La Fe, Valencia, Comunidad Valenciana, Spain, ⁹Pediatric Rheumatology Department. HUP La Fe, Valencia, Spain, ¹⁰Pediatric Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, ¹¹Hospital Universitari i Politècnic La Fe, Valencia, Spain
Background/Purpose: Juvenile idiopathic arthritis is the most common group of inflammatory rheumatic diseases in childhood. Its early onset and the immunosuppressive treatments used to control…
Abstract Number: 0416 • ACR Convergence 2025
Outcomes Of Children with Juvenile Idiopathic Arthritis Receiving Biological Disease-Modifying Anti-Rheumatic Drugs: Retrospective Analysis of A Real-World Experience From A Resource-Limited Setting
Narendra Bagri¹, Pavneet Kaur², Farheen KS², Bala Siva rama Krishna J², Banoth Sreesanth², Ayisha KP², Bareddy Sai Thrisha Reddy², ASHISH DATT UPADHYAY², RAKESH LODHA² and Sushil Kumar kabra², ¹All India Institute of Medical Sciences(AIIMS), New Delhi, Delhi, India, ²All India Institute of Medical Sciences, New Delhi, India
Background/Purpose: We aimed to study the outcomes (remission, flare, and adverse events) of biological disease-modifying anti-rheumatic drugs (bDMARD) in children with JIA from a low-middle-income…
Abstract Number: 0395 • ACR Convergence 2025
Association Between Body Mass Index (BMI) and JIA Inactive Disease at One Year
Anna Sutton¹ and Susan Shenoi², ¹University of Washington, Seattle, WA, ²Seattle Children's Hospital and Research Center, Mercer Island, WA
Background/Purpose: Among adults, higher BMI contributes to worse outcomes and reduced response to treatment in rheumatoid arthritis (RA), but this relationship is understudied among those…
Abstract Number: 2678 • ACR Convergence 2025
The Association Between Medication Taper Duration and Time to JIA Disease Flare: A Retrospective Cohort Study
Christian-Immanuel Oliveros¹, Kelly Rouster-Stevens², Laura Johnson³ and Sampath Prahalad⁴, ¹Emory University / Children's Healthcare of Atlanta, Atlanta, GA, ²Emory University/Children's Healthcare of Atlanta, Peachtree Corners, GA, ³Emory University, Atlanta, GA, ⁴Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Once clinically inactive, many patients with oligoarticular (oligoJIA) or polyarticular JIA (polyJIA) are interested in de-escalating therapy in a safe and successful manner. Many…
Abstract Number: 1829 • ACR Convergence 2025
Multiomic Investigation of Juvenile Idiopathic Arthritis Synovium Reveals Immune Cell Heterogeneity
Abigail Thielbar¹, Tracy Ting², Lexi Auld³, Kelly Rogers⁴, Megan Quinlan-Waters⁵, Sheila Angeles-Han⁴, Ekemini Ogbu², Daniel Lovell², Jennifer Huggins⁶, Grant Schulert², Patricia Vega-Fernandez² and Yuriy Baglaenko⁴, ¹Cincinnati Children's Hospital, Cincinnati, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, CCHMC, ⁶Cincinnati Children's Medical Center, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic disease of childhood, affecting 1:1,000 children worldwide. The hallmark of JIA is immune-mediated…
Abstract Number: 1252 • ACR Convergence 2025
Can LLMs Categorize Patient Priorities Like Humans? Comparing AI and Human Coders in Arthritis Nominal Group Discussions
Melissa Mannion¹, Bryce Thornton¹, Bella Mehta², Ronan O'Beirne¹, Emily Smitherman¹, Livie Timmerman³, Shilpa Venkatachalam⁴, Jeffrey Curtis¹ and John Osborne¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ, ³University of Alabama at Birmingham, Gardendale, AL, ⁴Global Healthy Living Foundation, New York, NY
Background/Purpose: Identifying informational needs of individuals with inflammatory arthritis is critical to enhancing communication and supporting shared decision making between patients, caregivers, and providers. However,…
Abstract Number: 0414 • ACR Convergence 2025
Predicting JIA-Associated Uveitis Using Tear Fluid Biomarkers: A Prospective Multicenter Study
Mariia Pavlenko¹, Mekibib Altaye², Hermine Brunner³, Margaret Chang⁴, Ashley Cooper⁵, Stefanie Davidson⁶, Alexandra Duell³, Bharti Gangwani⁴, Aimee Hersh⁷, Gary Holland⁸, Carl Langefeld⁹, Melissa Lerman¹⁰, Mindy Lo⁴, Virginia Miraldi Utz³, Sampath Prahalad¹¹, Grant Schulert³, Megan Quinlan-Waters¹², Erin Stahl⁵, Edmund Tsui⁸ and Sheila Angeles-Han¹³, ¹Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Boston Children's Hospital, Boston, MA, ⁵Children's Mercy Kansas City, Kansas City, MO, ⁶Department of Ophthalmology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, Philadelphia, PA, ⁷University of Utah, Salt Lake City, UT, ⁸UCLA Jules Stein Eye Institute and the Department of Ophthalmology, UCLA David Geffen School of Medicine, Los Angeles, ⁹Wake Forest University School of Medicine, Winston Salem, NC, ¹⁰Division of Rheumatology, Children's Hospital of Philadelphia and Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, Philadelphia, PA, ¹¹Emory + Children's Pediatric Institute, Atlanta, GA, ¹²Cincinnati Children's Hospital Medical Center, CCHMC, ¹³Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Uveitis is the most common extra-articular manifestation of juvenile idiopathic arthritis (JIA) and can lead to vision loss if not detected early. Current clinical…
Abstract Number: 0394 • ACR Convergence 2025
Predictors of quality of Life in a longitudinal cohort of patients with Uveitis, Juvenile Idiopathic Arthritis, and JIA-associated uveitis
andressa Guariento Ferreira Alves¹, Amy Cassedy², Virginia Miraldi Utz³, Alexandra Duell³, Megan Quinlan-Waters⁴, Nicole Reitz⁵, Sheila Angeles-Han⁶ and Melissa Lerman⁷, ¹The Children's Hospital of Philadelphia, Philadelphia, PA, ²Cincinnati Children's hospital medical center, cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, CCHMC, ⁵Department of Mental Health, St. Louis, MO, ⁶Cincinnati Children's Hospital, Cincinnati, OH, ⁷Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Uveitis, juvenile idiopathic arthritis (JIA), and JIA-associated uveitis (JIA-U) greatly influence children's quality of life (QOL). Our aim is to identify demographic, disease, and…
Abstract Number: 2675 • ACR Convergence 2025
RANTES and CXCL10 as Potential Tear-Based Biomarkers Associated with Ocular Damage in Pediatric Chronic Anterior Uveitis
Ilaria Maccora¹, Mariia Pavlenko², Mekibib Altaye³, Hermine Brunner⁴, Alexandra Duell⁴, Megan Quinlan-Waters⁵, Alyssa Sproles⁶, Sherry Thornton⁴, Grant Schulert⁴, Virginia Miraldi Utz⁴ and Sheila Angeles-Han⁶, ¹Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, ²Rheumatology Division, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA, Cincinnati, OH, ³Cincinnati Children's Hospital, Cincinnati, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, CCHMC, ⁶Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Pediatric chronic anterior uveitis (CAU) leads to sight-threatening complications in approximately 50% of affected children. Among complications, cataract and glaucoma are among the most…
Abstract Number: 1828 • ACR Convergence 2025
CD14+CXCL10+Monocytes Remodel the Peripheral Immune Network in sJIA via UBE2D1-Driven Inflammatory Programming
Xuemei Tang¹, Qiang Luo², Jun Yang³, Haiguo Yu⁴, Xinglin Wu¹, Xiwen Luo⁵, Xi Yang⁵, Zhiyong Zhang⁵, Yunfei An⁵, Xiaodong Zhao¹ and Hongmei Song⁶, ¹Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China, Chongqing, China (People's Republic), ²Department of Rheumatology and Immunology, Children’s Hospital of Chongqing Medical University, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China (People's Republic), ³Rheumatology and Immunology Department of Shenzhen Children's Hospital, Shenzhen, ⁵¹⁸¹⁰⁰, China., Shenzhen, China (People's Republic), ⁴Department of Rheumatology and Immunology, Nanjing Children's Hospital, Nanjing, ²¹⁰⁰⁰⁰, China., Nanjing, China (People's Republic), ⁵Department of Rheumatology & Immunology, Children’s Hospital of Chongqing Medical University, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, National Clinical Research Center for Child Health and Disorders (Chongqing), Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing, China., Chongqing, China (People's Republic), ⁶Pediatric Department of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, ¹⁰⁰⁰⁰⁰, China., Beijing, China (People's Republic)
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is an autoinflammatory disorder characterized by systemic immune dysregulation. However, reliable biomarkers to predict its unpredictable disease course are…
Abstract Number: 1066 • ACR Convergence 2025
Assessing Disparities in Outcomes and Processes of Care for Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
Julia Harris¹, Catherine Bingham², Sheetal Vora³, Jon Burnham⁴, Cagri Yildirim-Toruner⁵, Tzielan Lee⁶, Kerry Ferraro⁷, Erik Friedrichsen⁸, Katelyn Banschbach⁹, Michelle Batthish¹⁰, Danielle Fair¹¹, Mileka Gilbert¹², Beth Gottlieb¹³, Melissa Mannion¹⁴, Edward Oberle¹⁵, Nancy Pan¹⁶, Natalie Rosenwasser¹⁷, Mary Toth¹⁸, Jennifer Weiss¹⁹ and Esi Morgan¹⁷, ¹Children's Mercy Kansas City, Overland Park, KS, ²Penn State Children's Hospital, Hershey, PA, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Children's Hospital of Philadelphia, Bryn Mawr, PA, ⁵Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁶Stanford University School of Medicine, Palo Alto, CA, ⁷Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, ⁸Seattle Children's Hospital, Burien, WA, ⁹cincinnati Children's hospital, Villa Hills, KY, ¹⁰McMaster Children's Hospital, Hamilton, ON, Canada, ¹¹Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, ¹²Medical University of South Carolina, Charleston, SC, ¹³Cohen Children's Medical Center, Northwell Health, Lake Success, NY, ¹⁴University of Alabama at Birmingham, Birmingham, AL, ¹⁵Nationwide Children's Hospital, Columbus, OH, ¹⁶Hospital for Special Surgery, New York, NY, ¹⁷Seattle Children's Hospital, seattle, WA, ¹⁸Nemours Foundation, Orlando, FL, ¹⁹Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) has a mission to deliver exceptional and equitable health care to children with rheumatic diseases…
Abstract Number: 0413 • ACR Convergence 2025
Improving Access to Timely Joint Injections for Pediatric Rheumatology Patients – A Quality Improvement Initiative
Kendra Lauer¹, Vidya Sivaraman², Melissa Argraves³, Ysabella Esteban⁴, Laura Pratt⁵, Alysha Taxter⁶, Shoghik Akoghlanian³, Kelly Wise⁷, Kathryn Anliker³, Jonnie Hughes³, James Booker³, Ashlee Leone³ and Edward Oberle³, ¹Nationwide Children's Hospital, Dublin, OH, ²Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, ³Nationwide Children's Hospital, Columbus, OH, ⁴Nationwide Children's Hospital, Plain City, OH, ⁵Nationwide Children's Hospital/The Ohio State University College of Medicine, Columbus, OH, ⁶Nationwide Children's, Columbus, OH, ⁷Nationwide Children's Hospital, Hilliard, OH
Background/Purpose: Timely treatment for juvenile idiopathic arthritis (JIA) is essential for disease remission and decreasing risk of long-term morbidity. Intra-articular corticosteroid joint injections can treat…
Abstract Number: 0393 • ACR Convergence 2025
Effects of Self-Reported Medication Barriers on Medication Adherence and Disease Activity in a Cohort of Patients with Juvenile Idiopathic Arthritis
Aditi Shaily¹, Allison R. Eckard², Paul Nietert³, Emily Vara¹, Natasha Ruth⁴ and Mileka Gilbert³, ¹Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ²Departments of InternDivision of Infectious Diseases, Medical University of South Carolina, Charleston, SC, ³Medical University of South Carolina, Charleston, SC, ⁴Medical University South Carolina, Charleston, SC
Background/Purpose: Medications used to manage juvenile idiopathic arthritis (JIA) are highly effective in preventing joint damage and provide a favorable prognosis. Many patients, however, struggle…
Abstract Number: 2242 • ACR Convergence 2025
Analysis of Bronchoalveolar Fluid Cytokine Profile as a Way to Understand the Lung Disease Associated with Systemic Juvenile Idiopathic Arthritis
Ivanna Romankevych¹, Donna Do¹, Alyssa Sproles², Lexi Auld¹, Taskin Sabit¹, Richard Chhaing¹, Joy Baker¹, John Brewington³, Christopher Towe⁴, Alexiei GROM⁵ and Grant Schulert⁶, ¹Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Division of Pulmonary Medicine; University of Cincinnati, Cincinnati, OH, ⁴Cincinnati Children’s Hospital Medical Center, Division of Pulmonary medicine; University of Cincinnati, Cincinnati, OH, ⁵Cincinnati Children’s Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The lung disease associated with systemic JIA (SJIA-LD) remains poorly understood. Measurement of cytokine levels in bronchoalveolar lavage fluid (BALF) may offer insights into…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].